Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer.
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. Transl Lung Cancer Res. 2015 Dec; 4(6):704-12.